Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin

Phase 2 Completed 150 enrolled Gustave Roussy, Cancer Campus, Grand Paris Merck Serono International SA · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine - Oxaliplatin Chemotherapy Alone or in Combination with Cetuximab in Patients with Advanced Biliary Cancer.

Timeline

Start: 2007-10
Primary completion: 2012-04
Completion: 2012-04

Publications

Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardiere C, Boucher E, Fartoux L, Faivre S, Blanc JF, Viret F, Assenat E, Seufferlein T, Herrmann T, Grenier J, Hammel P, Dollinger M, Andre T, Hahn P, Heinemann V, Rousseau V, Ducreux M, Pignon JP, Wendum D, Rosmorduc O, Greten TF; BINGO investigators. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014 Jul;15(8):819-28. doi: 10.1016/S1470-2045(14)70212-8. Epub 2014 May 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cetuximab	Monoclonal antibody	500 mg/m2	Intravenous
Background	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Background	Oxaliplatin	Small molecule	100 mg/m2	Intravenous

Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin

Summary

Timeline

Publications

Drugs

Indications